A case of membranous nephropathy complicated by Cronkhite–Canada syndrome successfully treated with mizoribine
CEN Case Reports · 2024
DOI: 10.1007/s13730-024-00908-9 ↗Kurz gefasst
Fallbericht in der Zeitschrift CEN Case Reports, 2024. Verfasst von Hiroyuki Nakanoh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sc…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Intestinal Polyposis, Ribonucleosides, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cronkhite-Canada syndrome (CCS) is a non-hereditary disorder characterized by non-neoplastic hamartomatous gastrointestinal polyposis, hair loss, nail atrophy, hyperpigmentation, and diarrhea. While the relationship between CCS and nephritis remains unclear, seven cases of nephritis complicated by CCS have been reported to date, all of which were membranous nephropathy (MN). A 57-year-old man presented with taste disturbance, hair loss, nail plate atrophy, skin pigmentation, and frequent diarrhea. Endoscopic findings showed multiple polyposis of the stomach and large intestine. Given the above, he was diagnosed with CCS. The symptoms gradually improved with prednisolone treatment, although urinary protein and hypoproteinemia appeared during the tapering of prednisolone. He was diagnosed with MN using a renal biopsy, and immunofluorescence microscopy with IgG subclass staining showed predominantly diffuse granular capillary wall staining of IgG4. The cause of secondary MN was not found, including malignant tumors. Nephrotic-range proteinuria persisted despite treatment with prednisolone and cyclosporine. Additional treatment with mizoribine resulted in incomplete remission type 1 of nephrotic syndrome, suggesting that mizoribine may be a treatment option for patients with CCS with steroid-resistant MN. Considering a high prevalence of hypoproteinemia due to chronic diarrhea and protein-losing enteropathy in patients with CCS, proteinuria might be overlooked; thus, follow-up urinalysis would be recommended in patients with CCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Okayama, 700-8558, Japan.
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Okayama, 700-8558, Japan. ktsuji@s.okayama-…
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
ORCID-Profile: Kenji Tsuji
Zitieren
APA
Nakanoh, H., Tsuji, K., Morimoto, S., Fukushima, K., Iwamuro, M., Uchida, H. A., & Wada, J. (2024). A case of membranous nephropathy complicated by Cronkhite–Canada syndrome successfully treated with mizoribine. CEN Case Reports. https://doi.org/10.1007/s13730-024-00908-9
Vancouver
Nakanoh H, Tsuji K, Morimoto S, Fukushima K, Iwamuro M, Uchida HA, et al. A case of membranous nephropathy complicated by Cronkhite–Canada syndrome successfully treated with mizoribine. CEN Case Reports. 2024. doi:10.1007/s13730-024-00908-9
BibTeX
@article{Nakanoh2024,
author = {Nakanoh, Hiroyuki and Tsuji, Kenji and Morimoto, Shiho and Fukushima, Kazuhiko and Iwamuro, Masaya and Uchida, Haruhito A and Wada, Jun},
title = {A case of membranous nephropathy complicated by Cronkhite–Canada syndrome successfully treated with mizoribine},
journal = {CEN Case Reports},
year = {2024},
doi = {10.1007/s13730-024-00908-9}
}
EUVIMED